These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33300669)
1. Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Tsaliki M; Koelsch KA; Chambers A; Talsania M; Scofield RH; Chakravarty EF Int J Rheum Dis; 2021 Jan; 24(1):120-124. PubMed ID: 33300669 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Medeiros MM; Silveira VA; Menezes AP; Carvalho RC Braz J Med Biol Res; 2001 Dec; 34(12):1561-8. PubMed ID: 11717709 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand. Akawatcharangura P; Taechakraichana N; Osiri M Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134 [TBL] [Abstract][Full Text] [Related]
4. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. McDermott EM; Powell RJ Ann Rheum Dis; 1996 Apr; 55(4):224-9. PubMed ID: 8733438 [TBL] [Abstract][Full Text] [Related]
5. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312 [TBL] [Abstract][Full Text] [Related]
6. Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide. Singh G; Misra R; Aggarwal A J Assoc Physicians India; 2016 Feb; 64(2):28-31. PubMed ID: 27730777 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Mayorga J; Alpízar-Rodríguez D; Prieto-Padilla J; Romero-Díaz J; Cravioto MC Lupus; 2016 Jun; 25(7):675-83. PubMed ID: 26678443 [TBL] [Abstract][Full Text] [Related]
8. Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy. Sen M; Kurl A; Khosroshahi A Lupus; 2021 Aug; 30(9):1509-1514. PubMed ID: 34053364 [TBL] [Abstract][Full Text] [Related]
10. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Katsifis GE; Tzioufas AG Lupus; 2004; 13(9):673-8. PubMed ID: 15485101 [TBL] [Abstract][Full Text] [Related]
11. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy]. Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002 [TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus. Wolf VL; Taylor EB; Ryan MJ Physiol Rep; 2019 May; 7(10):e14059. PubMed ID: 31124322 [TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. Singh G; Saxena N; Aggarwal A; Misra R J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229 [TBL] [Abstract][Full Text] [Related]
14. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. Mok CC; Chan PT; To CH Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647 [TBL] [Abstract][Full Text] [Related]
16. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Luborsky J; Llanes B; Davies S; Binor Z; Radwanska E; Pong R Clin Immunol; 1999 Mar; 90(3):368-74. PubMed ID: 10075866 [TBL] [Abstract][Full Text] [Related]
17. Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. Oktem O; Guzel Y; Aksoy S; Aydin E; Urman B Obstet Gynecol Surv; 2015 Mar; 70(3):196-210. PubMed ID: 25769434 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide therapy induces ovarian failure in premenopausal women affected by systemic lupus erythematosus. Tincani A Clin Exp Rheumatol; 2001; 19(5):490-1. PubMed ID: 11579705 [No Abstract] [Full Text] [Related]
19. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M Lupus; 2000; 9(6):401-5. PubMed ID: 10981642 [TBL] [Abstract][Full Text] [Related]
20. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Manger K; Wildt L; Kalden JR; Manger B Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]